Publicaciones (46) Publicaciones de MARÍA DOLORES GUTIÉRREZ LÓPEZ

2022

  1. Influx of kynurenine into the brain is involved in the reduction of ethanol consumption induced by Ro 61-8048 after chronic intermittent ethanol in mice

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3711-3726

2021

  1. Addiction and the kynurenine pathway: A new dancing couple?

    Pharmacology and Therapeutics, Vol. 223

  2. Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor

    Neuropharmacology, Vol. 187

2019

  1. Changes in brain kynurenine levels via gut microbiota and gut-barrier disruption induced by chronic ethanol exposure in mice

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 33, Núm. 11, pp. 12900-12914

2018

  1. Increasing kynurenine brain levels reduces ethanol consumption in mice by inhibiting dopamine release in nucleus accumbens

    Neuropharmacology, Vol. 135, pp. 581-591

2017

  1. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus

    Neuropharmacology, Vol. 118, pp. 157-166

  2. Disruption of blood–brain barrier integrity in postmortem alcoholic brain: preclinical evidence of TLR4 involvement from a binge-like drinking model

    Addiction Biology, Vol. 22, Núm. 4, pp. 1103-1116

2014

  1. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 8, pp. 1243-1255

  2. The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 2, pp. 235-246

2013

  1. A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine

    Neurobiology of Disease, Vol. 50, Núm. 1, pp. 49-58

  2. ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9

    Cellular and Molecular Life Sciences, Vol. 70, Núm. 3, pp. 475-493

  3. Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: Implications for the pathogenesis of free radical-induced neurodegenerative disorders

    Psychopharmacology, Vol. 230, Núm. 1, pp. 125-135

  4. Implicación de la molécula de adhesión ALCAM en el daño cerebral. Modelo de daño neuronal mediante la administración de MDMA/éxtasis en rata

    Trauma (Spain), Vol. 24, Núm. 2, pp. 101-108

2012

  1. Velázquez. Manual de farmacología básica y clínica col.

    Editorial Médica Panamericana

2011

  1. Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): Regulation by CB2 receptors and implications for neurotoxicity

    Journal of Neuroinflammation, Vol. 8

  2. Functional interplay between tetraspanins and proteases

    Cellular and Molecular Life Sciences, Vol. 68, Núm. 20, pp. 3323-3335

  3. Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA

    Journal of Neuroinflammation, Vol. 8

  4. The sheddase activity of ADAM17/TACE is regulated by the tetraspanin CD9

    Cellular and Molecular Life Sciences, Vol. 68, Núm. 19, pp. 3275-3292

2010

  1. Administration of neurotoxic doses of MDMA reduces sensitivity to ethanol and increases GAT-1 immunoreactivity in mice striatum

    Psychopharmacology, Vol. 207, Núm. 4, pp. 671-679

  2. Desarrollo de un Modelo Estadístico Universal para Proteómica Cuantitativa mdiante Marcaje IsotÓpico Estable

    Proteómica: revista de la Sociedad Española de Proteómica, Núm. 5, pp. 101-103